Press releases
- Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
- Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
- Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 188.26 |
Average volume | -- |
---|---|
Shares outstanding | 602.60m |
Free float | 597.18m |
P/E (TTM) | 37.59 |
Market cap | 52.70bn USD |
EPS (TTM) | 2.33 USD |
Data delayed at least 15 minutes, as of Jun 25 2019.
More ▼